top of page

Loncar Cancer Immunotherapy Index Conducts Semi-Annual Rebalance


Five Biotechnology Companies Added to the Index


Lenexa, KS -- December 21, 2021 -- Loncar Investments, LLC today announced the result of the semi-annual rebalance and reconstitution of the Loncar Cancer Immunotherapy Index, a stock index of top companies developing cancer immunotherapy treatments and discovering new ways to use the body’s immune system to fight cancer. 

For the December meeting, the committee has added five immunotherapy companies. They are Caribou Biosciences (Nasdaq: CRBU), Immunocore (Nasdaq: IMCR), Inhibrx (Nasdaq: INBX), iTeos Therapeutics (Nasdaq: ITOS), Merus (Nasdaq: MRUS).


These companies replace IGM Biosciences (Nasdaq: IGMS), Shattuck Labs (Nasdaq: STTK), Y-mAbs Therapeutics (Nasdaq: YMAB), Zymeworks (NYSE: ZYME), and 2seventy bio (Nasdaq: TSVT).

Brad Loncar, CEO of Loncar Investments and Chairman of the Index Committee, had the following comments, “2021 has been a difficult year for the biotechnology sector at large and the immunotherapy field specifically. Mergers and acquisitions were sparse this year, regulatory uncertainty relating to drug pricing has been in headlines, and the ongoing pandemic slowed some cancer trials. However, I am optimistic that tangible progress is being made on the scientific level as new immune targets, particularly CD47, TIGIT, and LAG-3, have produced promising data at medical conferences. The bi-specific antibody approach to immunotherapy also closed the year strong with encouraging data presented at the recent American Society of Hematology Annual Meeting. Some of the companies being added today are focused on these fast-moving areas of science. We are pleased to support the important work they do and wish them all the best.”


Effective this week, all index holdings have been rebalanced to hold equal weight. The index is rebalanced and reconstituted semi-annually. The next rebalance will occur on June 21, 2022. 


Loncar Investments is an official partner of the Cancer Research Institute, the world’s longest running nonprofit organization dedicated exclusively to harnessing the immune system’s power to conquer all cancers. To learn about how to give to CRI, please visit here.


Why immunotherapy:  Cancer immunotherapy has become an important sector in the biotechnology space and is changing the way many cancers are treated. While traditional medicines like chemotherapies often give cancer a broad punch, the benefit of using immunotherapy is derived from the immune system's dynamic nature and the way it can more precisely be tailored to fight a patient's disease.  


About the index:  The Loncar Cancer Immunotherapy Index is an equal-weighted index of top immunotherapy companies rebalanced and reconstituted on a semi-annual basis. Price and return data are independently calculated on a daily basis by Indxx, LLC. Additional information can be found at the index’s dedicated website,


Index provider:  Loncar Investments, LLC is committed to making the biotechnology space more approachable to a wider range of investors. It incorporates extensive research into biotech companies and technologies to develop stock market indexes that are focused on precise investment opportunities. The company is principally owned by biotech investor and analyst Brad Loncar.




Loncar Investments, LLC

Jill Tatios, 215-240-6398


Loncar Investments, LLC : P.O Box 15072, Lenexa, KS  66285 : 913-871-5007 : Not investment advice or a solicitation to buy or sell securities

bottom of page